Home Alzheimer’s Disease Clinically Meaningful Benefit in Advanced KRAS G12C+ NSCLC Is Seen With Sotorasib

Clinically Meaningful Benefit in Advanced KRAS G12C+ NSCLC Is Seen With Sotorasib

Patients with advanced non–small cell lung cancer (NSCLC) harboring KRAS G12C mutations benefitted from therapy with sotorasib (formerly AMG 510), an inhibitor of KRAS G12C, which induced a 6.8-month median progression-free survival. These results from the CodeBreaK 100 trial (NCT03600883) were presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.1,2

The confirmed objective response rate (ORR) and a disease control rate were 37.1% and 80.6%, respectively, at a median follow-up of 12.2 months. The median duration of response was 10 months.

These data show that sotorasib is the first KRAS G12C inhibitor to show PFS in a phase 2 study, stated Amgen, the manufacturer of the agent.

“These results are encouraging and clinically meaningful for patients with advanced NSCLC harboring the KRAS G12C mutation,” said lead…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Recent Comments